Professor | Liming Shao | Asia Growth Partners

	Upload Avatar (500 x 500)
Name	Liming Shao
Contact Information	limingshao@fudan.edu.cn
Language ability	Chinese, Japanese, English
Province	Shanghai

Upload Avatar (500 x 500)

Name

Liming Shao

Contact Information

limingshao@fudan.edu.cn

Language ability

Chinese, Japanese, English

Province

Shanghai

University/Lab Affiliation and Title	Fudan University
Faculty	Pharmaceutical Sciences
Academic Background & Achievements	1978.09 – 1982.07 Bachelor of Science in Organic Chemistry: Fudan University 1987.09 – 1990.03 Master of Engineering in Industrial Chemistry: University of Tokyo 1990.03 – 1993.03 Doctor of Engineering in Industrial Chemistry: University of Tokyo 1993.04 – 1996.08 Postdoctoral Researcher in Chemistry and Chemical Biology: Harvard University Led and participated in the research and development of various drugs, with 4 compounds approved by the US FDA for clinical trials Participated in the development of contraceptives, with one drug approved by the China FDA for market
Work Experience	1982.08 – 1987.05 WHO Human Reproduction Research Center/Shanghai Institute of Planned Parenthood Research, Assistant Researcher 1998.09 – 2010.10 Sepracor Inc., Drug Development and Preclinical Research Department (USA, Massachusetts) 2008-2010 Senior Director 2005-2008 Director 2001-2005 Associate Director 2000-2001 Senior Scientist 1998-2000 Scientist 2010.10 – 2012.05 Sunovion Inc., Preclinical Research and Translational Medicine Department (USA, Massachusetts), Senior Director 2012.06 – Present Fudan University School of Pharmacy, Professor

University/Lab Affiliation and Title

Fudan University

Faculty

Pharmaceutical Sciences

Academic Background & Achievements

1978.09 – 1982.07 Bachelor of Science in Organic Chemistry: Fudan University
1987.09 – 1990.03 Master of Engineering in Industrial Chemistry: University of Tokyo
1990.03 – 1993.03 Doctor of Engineering in Industrial Chemistry: University of Tokyo
1993.04 – 1996.08 Postdoctoral Researcher in Chemistry and Chemical Biology: Harvard University
Led and participated in the research and development of various drugs, with 4 compounds approved by the US FDA for clinical trials
Participated in the development of contraceptives, with one drug approved by the China FDA for market

Work Experience

1982.08 – 1987.05 WHO Human Reproduction Research Center/Shanghai Institute of Planned Parenthood Research, Assistant Researcher
1998.09 – 2010.10 Sepracor Inc., Drug Development and Preclinical Research Department (USA, Massachusetts)
2008-2010 Senior Director
2005-2008 Director
2001-2005 Associate Director
2000-2001 Senior Scientist
1998-2000 Scientist
2010.10 – 2012.05 Sunovion Inc., Preclinical Research and Translational Medicine Department (USA, Massachusetts), Senior Director
2012.06 – Present Fudan University School of Pharmacy, Professor

Areas of Focus	Rational design, synthesis, and research and development of diagnostic and therapeutic drugs for central nervous system diseases Research and development of therapeutic drugs for malignant tumors Research and development of new methods for drug discovery (new synthetic methods, druggability, structural biology) Exploration of translational medicine methods in drug research
Publications	Discovery of Potent and Selective Transient Receptor Potential Vanilloid 1 (TRPV1) Agonists with Analgesic Effects In Vivo Based on the Functional Conversion Induced by Altering the Orientation of the Indazole Core, Liang, Q.Q.; Qiao, Z.; Zhou, Q.Q.; Xue, D.Q.; Wang, K.W.; Shao, L.M., 2022 SLL-627 Is a Highly Selective and Potent Kappa Opioid Receptor (KOR) Agonist with an Unexpected Nonreduction in Locomotor Activity, Kong, L. H.; Shu, X. L.; Tang, S. Y.; Ye, R. R.; Sun, H. J.; Jiang, S.; Li, Z. X.; Chai, J. R.; Fang, Y.; Lan, Y. J.; Yu, L. Q.; Xie, Q.; Fu, W.; Wang, Y. J.; Li, W.; Qiu, Z. B.; Liu, J. G.; Shao, L. M., 2022 Design and development of selective competitive fluorescent ligands for the detection and visualization of Kv7.2/7.3 in vitro, Qiao, Z.; Tang, S. Y.; Guan, J. L.; Yin, Z. J.; Zhu, C.; Zhou, Q. Q.; Shao, L. M., 2022 Novel selective kappa agonists SLL-039 and SLL-1206 produce potent antinociception with fewer sedation and aversion, Wei, Y. Y.; Ma, Y.; Yao, S. Y.; Kong, L. H.; Liu, X.; Chai, J. R.; Chen, J.; Li, W.; Wang, Y. J.; Shao, L. M.; Liu, J. G., 2022 Design and synthesis of novel alpha-aminoamides derivatives as Nav1.7 inhibitors for antinociception, Xue, D. Q.; Liu, Y. N.; Zheng, Y. L.; Niu, H. L.; Dong, L. Y.; Ouyang, X. S.; Song, S. Y.; Zhang, D. G.; Ge, Q. W.; Wang, K. W.; Shao, L. M., 2022 A covalent modification strategy for di-alkyne tagged metal-organic frameworks to access efficient heterogeneous catalysts toward C-C bond formation, Liang, Q. Q.; Cheng, H.; Li, C. W.; Ning, L. M.; Shao, L. M., 2022 Iron-catalyzed radical cascade cyclization of oxime esters with isocyanides: synthesis of 1-cyanoalkyl isoquinolines and 6-cyanoalkyl phenanthridines, Xue, D. Q.; Liu, R. Q.; Zhang, D. G.; Li, N.; Xue, Y. J.; Ge, Q. W.; Shao, L. M., 2021 Nickel- alkyne-functionalized metal-organic frameworks: An efficient and reusable catalyst, Chen, H.; N., L.M.; Liao, S. Y.; Li, W.; Tang, S. Y.; Li, J. L.; Chen, H. X.; Liu, X.; Shao, L. M., 2021 Exploration of the SAR Connection between Morphinan- and Arylacetamide-Based kappa Opioid Receptor (kappa OR) Agonists Using the Strategy of Bridging, Liu, X.; Jiang, S.; Kong, L. H.; Ye, R. R.; Xiao, L.; Xu, X. J.; He, Q.; Wei, Y. Y.; Li, Z. X.; Sun, H. J.; Xie, Q.; Xu, X.; Lu, Y.; Wang, Y. J.; Li, W.; Fu, W.; Qiu, Z. B.; Liu, J. G.; Shao, L. M., 2021 Discovery of an M-Substituted N-Cyclopropylmethyl-7alpha-phenyl-6,14-endoethanotetrahydronorthebaine as a Selective, Potent, and Orally Active kappa-Opioid Receptor Agonist with an Improved Central Nervous System Safety Profile, He, Q.; Wei, Y.; Liu, X.; Ye, R.; Kong, L.; Li, Z.; Jiang, S.; Yu, L.; Chai, J.; Xie, Q.; Fu, W.; Wang, Y.J.; Li, W.; Qiu, Z.; Liu, J.G.; Shao, L.M., 2021 Inhibition of Nav1.7 channel by a novel blocker QLS-81 for alleviation of neuropathic pain, Niu, H. L.; Liu, Y. N.; Xue, D. Q.; Dong, L. Y.; Liu, H. J.; Wang, J.; Zheng, Y. L.; Zou, A. R.; Shao, L. M.; Wang, K. W., 2021 Additive-Free Radical Cascade Reaction of Oxime Esters: Synthesis of Pyrroline-Functionalized Phenanthridines, Xue, Y. J.; Xue, D. Q.; He, Q.; Ge, Q. W.; Li, W.; Shao, L. M., 2020 Palladium-Catalyzed Synthesis of beta,beta-Diaryl alpha,beta-Unsaturated Ketones, Zheng, Y. L.; Xiao, L.; Xie, Q.; Shao, L. M., 2019 Metal-Free Radical Cyclization of Vinyl Isocyanides with Alkanes: Synthesis of 1-Alkylisoquinolines, Xue, D. Q.; Xue, Y. J.; Yu, H. H.; Shao, L. M., 2019 Discovery of a Highly Selective and Potent kappa Opioid Receptor Agonist from N-Cyclopropylmethyl-7alpha-phenyl-6,14-endoethanotetrahydronorthebaines with Reduced Central Nervous System (CNS) Side Effects Navigated by the Message-Address Concept, Xiao, L.; Wang, Y.J.; Zhang, M.M.; Wu, W.; Kong, L.; Ma, Y.; Xu, X.; Liu, X.; He, Q.; Qian, Y.; Sun, H.; Wu, H.; Lin, C.; Huang, H.; Ye, R.; Jiang, S.; Ye, R. F.; Yuan, C.; Fang, S.; Xue, D.; Yang, X.; Chen, H.; Zheng, Y.; Yu, L.; Xie, Q.; Zheng, L.; Fu, W.; Li, W.; Qiu, Z.B.; Liu, J.G.; Shao, L.M., 2019 Nickel-Catalyzed Construction of 2,4-Disubstituted Imidazoles via C-C Coupling and C-N Condensation Cascade Reactions, Fang, S. Y.; Yu, H. H.; Yang, X. C.; Li, J. Q.; Shao, L. M., 2019 Discovery, cocrystallization and biological evaluation of novel piperidine derivatives as high affinity Ls-AChBP ligands possessing alpha 7 nAChR activities, Yang, X. C.; Shen, J.; Jiang, L. L.; Li, W.; Yu, M. C.; Pan, G. X.; Yan, Y. R.; Zhang, C. H.; Jia, W. W.; Xiao, L.; Yu, H. H.; Chen, H.; Zheng, Y. L.; Yu, L. Q.; Xie, Q.; Zhou, L.; Shao, L. M., 2018 Regioselective Access to 3-Aryl-1-aminoisoquinolines via Nickel(I)-Catalyzed C-C and C-N Cascade Coupling Reactions from the Substituted 2-(Cyanomethyl)benzonitriles, Yang, X.; Yu, H.; Xu, Y.; Shao, L.M., 2018 Discovery of novel 20S proteasome inhibitors by rational topology-based scaffold hopping of bortezomib

Areas of Focus

Rational design, synthesis, and research and development of diagnostic and therapeutic drugs for central nervous system diseases
Research and development of therapeutic drugs for malignant tumors
Research and development of new methods for drug discovery (new synthetic methods, druggability, structural biology)
Exploration of translational medicine methods in drug research

Publications

Discovery of Potent and Selective Transient Receptor Potential Vanilloid 1 (TRPV1) Agonists with Analgesic Effects In Vivo Based on the Functional Conversion Induced by Altering the Orientation of the Indazole Core, Liang, Q.Q.; Qiao, Z.; Zhou, Q.Q.; Xue, D.Q.; Wang, K.W.; Shao, L.M., 2022
SLL-627 Is a Highly Selective and Potent Kappa Opioid Receptor (KOR) Agonist with an Unexpected Nonreduction in Locomotor Activity, Kong, L. H.; Shu, X. L.; Tang, S. Y.; Ye, R. R.; Sun, H. J.; Jiang, S.; Li, Z. X.; Chai, J. R.; Fang, Y.; Lan, Y. J.; Yu, L. Q.; Xie, Q.; Fu, W.; Wang, Y. J.; Li, W.; Qiu, Z. B.; Liu, J. G.; Shao, L. M., 2022
Design and development of selective competitive fluorescent ligands for the detection and visualization of Kv7.2/7.3 in vitro, Qiao, Z.; Tang, S. Y.; Guan, J. L.; Yin, Z. J.; Zhu, C.; Zhou, Q. Q.; Shao, L. M., 2022
Novel selective kappa agonists SLL-039 and SLL-1206 produce potent antinociception with fewer sedation and aversion, Wei, Y. Y.; Ma, Y.; Yao, S. Y.; Kong, L. H.; Liu, X.; Chai, J. R.; Chen, J.; Li, W.; Wang, Y. J.; Shao, L. M.; Liu, J. G., 2022
Design and synthesis of novel alpha-aminoamides derivatives as Nav1.7 inhibitors for antinociception, Xue, D. Q.; Liu, Y. N.; Zheng, Y. L.; Niu, H. L.; Dong, L. Y.; Ouyang, X. S.; Song, S. Y.; Zhang, D. G.; Ge, Q. W.; Wang, K. W.; Shao, L. M., 2022
A covalent modification strategy for di-alkyne tagged metal-organic frameworks to access efficient heterogeneous catalysts toward C-C bond formation, Liang, Q. Q.; Cheng, H.; Li, C. W.; Ning, L. M.; Shao, L. M., 2022
Iron-catalyzed radical cascade cyclization of oxime esters with isocyanides: synthesis of 1-cyanoalkyl isoquinolines and 6-cyanoalkyl phenanthridines, Xue, D. Q.; Liu, R. Q.; Zhang, D. G.; Li, N.; Xue, Y. J.; Ge, Q. W.; Shao, L. M., 2021
Nickel- alkyne-functionalized metal-organic frameworks: An efficient and reusable catalyst, Chen, H.; N., L.M.; Liao, S. Y.; Li, W.; Tang, S. Y.; Li, J. L.; Chen, H. X.; Liu, X.; Shao, L. M., 2021
Exploration of the SAR Connection between Morphinan- and Arylacetamide-Based kappa Opioid Receptor (kappa OR) Agonists Using the Strategy of Bridging, Liu, X.; Jiang, S.; Kong, L. H.; Ye, R. R.; Xiao, L.; Xu, X. J.; He, Q.; Wei, Y. Y.; Li, Z. X.; Sun, H. J.; Xie, Q.; Xu, X.; Lu, Y.; Wang, Y. J.; Li, W.; Fu, W.; Qiu, Z. B.; Liu, J. G.; Shao, L. M., 2021
Discovery of an M-Substituted N-Cyclopropylmethyl-7alpha-phenyl-6,14-endoethanotetrahydronorthebaine as a Selective, Potent, and Orally Active kappa-Opioid Receptor Agonist with an Improved Central Nervous System Safety Profile, He, Q.; Wei, Y.; Liu, X.; Ye, R.; Kong, L.; Li, Z.; Jiang, S.; Yu, L.; Chai, J.; Xie, Q.; Fu, W.; Wang, Y.J.; Li, W.; Qiu, Z.; Liu, J.G.; Shao, L.M., 2021
Inhibition of Nav1.7 channel by a novel blocker QLS-81 for alleviation of neuropathic pain, Niu, H. L.; Liu, Y. N.; Xue, D. Q.; Dong, L. Y.; Liu, H. J.; Wang, J.; Zheng, Y. L.; Zou, A. R.; Shao, L. M.; Wang, K. W., 2021
Additive-Free Radical Cascade Reaction of Oxime Esters: Synthesis of Pyrroline-Functionalized Phenanthridines, Xue, Y. J.; Xue, D. Q.; He, Q.; Ge, Q. W.; Li, W.; Shao, L. M., 2020
Palladium-Catalyzed Synthesis of beta,beta-Diaryl alpha,beta-Unsaturated Ketones, Zheng, Y. L.; Xiao, L.; Xie, Q.; Shao, L. M., 2019
Metal-Free Radical Cyclization of Vinyl Isocyanides with Alkanes: Synthesis of 1-Alkylisoquinolines, Xue, D. Q.; Xue, Y. J.; Yu, H. H.; Shao, L. M., 2019
Discovery of a Highly Selective and Potent kappa Opioid Receptor Agonist from N-Cyclopropylmethyl-7alpha-phenyl-6,14-endoethanotetrahydronorthebaines with Reduced Central Nervous System (CNS) Side Effects Navigated by the Message-Address Concept, Xiao, L.; Wang, Y.J.; Zhang, M.M.; Wu, W.; Kong, L.; Ma, Y.; Xu, X.; Liu, X.; He, Q.; Qian, Y.; Sun, H.; Wu, H.; Lin, C.; Huang, H.; Ye, R.; Jiang, S.; Ye, R. F.; Yuan, C.; Fang, S.; Xue, D.; Yang, X.; Chen, H.; Zheng, Y.; Yu, L.; Xie, Q.; Zheng, L.; Fu, W.; Li, W.; Qiu, Z.B.; Liu, J.G.; Shao, L.M., 2019
Nickel-Catalyzed Construction of 2,4-Disubstituted Imidazoles via C-C Coupling and C-N Condensation Cascade Reactions, Fang, S. Y.; Yu, H. H.; Yang, X. C.; Li, J. Q.; Shao, L. M., 2019
Discovery, cocrystallization and biological evaluation of novel piperidine derivatives as high affinity Ls-AChBP ligands possessing alpha 7 nAChR activities, Yang, X. C.; Shen, J.; Jiang, L. L.; Li, W.; Yu, M. C.; Pan, G. X.; Yan, Y. R.; Zhang, C. H.; Jia, W. W.; Xiao, L.; Yu, H. H.; Chen, H.; Zheng, Y. L.; Yu, L. Q.; Xie, Q.; Zhou, L.; Shao, L. M., 2018
Regioselective Access to 3-Aryl-1-aminoisoquinolines via Nickel(I)-Catalyzed C-C and C-N Cascade Coupling Reactions from the Substituted 2-(Cyanomethyl)benzonitriles, Yang, X.; Yu, H.; Xu, Y.; Shao, L.M., 2018
Discovery of novel 20S proteasome inhibitors by rational topology-based scaffold hopping of bortezomib

Central Nervous System Drug Design Synthesis Therapeutic Drugs Malignant Tumors Drug Discovery Synthetic Methods Druggability Structural Biology Translational Medicine

Rongqin Huang - Fudan University

Wei Li - Fudan University

Yingxia Li - Fudan University

View All

Personal Information

Academic Information

Research

Contact us

No account yet?

Personal Information

Academic Information

Research

Contact us